Market Analysts see Synthetic Biologics Inc. [SYN] gaining to $6. Time to buy?

Synthetic Biologics Inc. [AMEX: SYN] stock went on a downward path that fall over -8.63% on Thursday, amounting to a one-week price decrease of less than -18.58%. The company report on April 14, 2021 that Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced enrollment has commenced and the first patient has been dosed in its Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). Broad spectrum intravenous (IV) beta-lactam antibiotics used to treat infection following conditioning chemotherapy for allogeneic HCT patients is a necessary and oftentimes lifesaving intervention. However, antibiotic-mediated damage of the gut microbiome in this patient population has been strongly associated with adverse outcomes including C. difficile infection (CDI), vancomycin-resistant enterococci (VRE) colonization, potentially fatal bacteremia, and aGVHD.

“Allogenic HCT recipients are at very high risk for infection and frequently receive antibiotics,” said Erik Dubberke, MD, Professor of Medicine and Clinical Director of Transplant Infectious Diseases at Washington University School of Medicine in St. Louis. “There is increasing evidence that disruption of the microbiome caused by antibiotics results in additional complications, including further infections. If this trial shows that SYN-004 has a favorable safety profile and is able to protect the microbiome, it would warrant study in larger trials to determine if this treatment can improve outcomes in these highly susceptible patients.”.

Over the last 12 months, SYN stock rose by 53.08%. The average equity rating for SYN stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $68.61 million, with 129.66 million shares outstanding and 127.36 million shares in the current float. Compared to the average trading volume of 15.24M shares, SYN stock reached a trading volume of 4019863 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Synthetic Biologics Inc. [SYN]:

FBR & Co. have made an estimate for Synthetic Biologics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 06, 2017. While these analysts kept the previous recommendation, FBR Capital raised their target price from $10 to $9. The new note on the price target was released on May 06, 2016, representing the official price target for Synthetic Biologics Inc. stock. Previously, the target price had yet another raise to $10, while FBR Capital analysts kept a Outperform rating on SYN stock.

The Average True Range (ATR) for Synthetic Biologics Inc. is set at 0.07

SYN Stock Performance Analysis:

Synthetic Biologics Inc. [SYN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.58. With this latest performance, SYN shares dropped by -34.30% in over the last four-week period, additionally plugging by 62.83% over the last 6 months – not to mention a rise of 53.08% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SYN stock in for the last two-week period is set at 33.37, with the RSI for the last a single of trading hit 24.84, and the three-weeks RSI is set at 38.65 for Synthetic Biologics Inc. [SYN]. The present Moving Average for the last 50 days of trading for this stock 0.7581, while it was recorded at 0.5911 for the last single week of trading, and 0.5582 for the last 200 days.

Insight into Synthetic Biologics Inc. Fundamentals:

Return on Total Capital for SYN is now -113.27, given the latest momentum, and Return on Invested Capital for the company is -87.12. Return on Equity for this stock declined to -89.69, with Return on Assets sitting at -78.32. When it comes to the capital structure of this company, Synthetic Biologics Inc. [SYN] has a Total Debt to Total Equity ratio set at 5.89. Additionally, SYN Total Debt to Total Capital is recorded at 5.56, with Total Debt to Total Assets ending up at 5.62.

Reflecting on the efficiency of the workforce at the company, Synthetic Biologics Inc. [SYN] managed to generate an average of -$1,004,300 per employee.Synthetic Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.


With the latest financial reports released by the company, Synthetic Biologics Inc. posted -0.2/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SYN.

Synthetic Biologics Inc. [SYN] Insider Position Details

There are presently around $1 million, or 1.50% of SYN stock, in the hands of institutional investors. The top three institutional holders of SYN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,237,733, which is approximately 43.967% of the company’s market cap and around 1.77% of the total institutional ownership; FISHER ASSET MANAGEMENT, LLC, holding 125,698 shares of the stock with an approximate value of $73000.0 in SYN stocks shares; and BRIDGEWAY CAPITAL MANAGEMENT, LLC, currently with $63000.0 in SYN stock with ownership of nearly 0% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Synthetic Biologics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 7 institutional holders increased their position in Synthetic Biologics Inc. [AMEX:SYN] by around 579,838 shares. Additionally, 6 investors decreased positions by around 102,113 shares, while 11 investors held positions by with 1,163,747 shares. The mentioned changes placed institutional holdings at 1,845,698 shares, according to the latest SEC report filing. SYN stock had 2 new institutional investments in for a total of 120,090 shares, while 3 institutional investors sold positions of 109 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam